Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study
ClinicalTrials.gov NCT03518034
Research payments
$11,791,573
Through program year 2021, $11,791,573 in research payments was reported against Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study, across 3,641 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT03518034
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $11,791,573 | 3,641 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Allan Dinnerstein Fort Stewart, GA Named on 133 payments
- Arvind Krishna Canton, OH Named on 81 payments
- Cynthia Brinson Austin, TX Named on 60 payments
- Andrew Drabick Raleigh, NC Named on 39 payments
- Pamela Moore Plano, TX Named on 37 payments
- Steven Leichter Columbus, GA Named on 34 payments
- Sabrina Benjamin Olympia, WA Named on 34 payments
- Kwabena Ayesu Orlando, FL Named on 34 payments
- Gretel Trullenque Miami Lakes, FL Named on 30 payments
- Kim Barbel-Johnson Jacksonville, FL Named on 30 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.